Overview Dividends

(STE) STERIS - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: IE00BFY8C754

Sterilizers, Disinfectants, Washers, Tables, Services

STE EPS (Earnings per Share)

EPS Growth (3Y CAGR): 7.59%
EPS Trend (3Y Correlation): 62.3%

STE Revenue

Revenue Growth (3Y CAGR): 6.88%
Revenue Trend (3Y Correlation): 63.7%

Risk via 10d forecast
Volatility	22.2%
Value at Risk 5%th	33.8%

Reward
Sharpe Ratio	0.86
Alpha	0.20

Character
Hurst Exponent	0.448
Beta	1.026

Drawdowns 3y
Max DD	19.93%
Mean DD	6.82%

Description: STE STERIS October 14, 2025

STERIS plc (NYSE: STE) is a U.S.–based provider of infection-prevention products and services, organized into three operating segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment supplies cleaning chemistries, endoscope reprocessing systems, sterilizers, surgical tables, lights, and related capital-equipment services; the AST segment offers contract sterilization and testing for medical-device and pharmaceutical manufacturers; and the Life Sciences segment manufactures consumables (e.g., detergents, disinfectants, vaporized-hydrogen-peroxide systems) and high-purity water/steam generators, together with installation and maintenance contracts.

In fiscal 2023 STE reported revenue of roughly $4.1 billion, with an adjusted operating margin of about 12 % and free-cash-flow conversion near 15 %. Growth has been driven by two secular trends: (1) rising global demand for infection-control solutions amid heightened awareness of hospital-acquired infections, and (2) expanding outsourcing of sterilization by pharmaceutical and med-device firms seeking to reduce capital-expenditure cycles. The 2022 acquisition of Integrated Healthcare Solutions added endoscope-reprocessing capabilities, which analysts estimate contributed ~3-4 % of FY2023 revenue.

Key macro drivers include aging populations (increasing procedure volumes), tighter regulatory standards for sterility assurance, and supply-chain pressures on high-purity water and steam equipment-factors that can amplify STE’s pricing power but also introduce execution risk. Assuming continued FY-24 revenue growth of 5-6 % and stable margins, the company’s valuation could be sensitive to changes in contract-sterilization demand and capital-equipment replacement cycles.

For a deeper quantitative assessment, the ValueRay platform provides granular cash-flow and valuation models that let you test these assumptions and explore scenario outcomes.

STE Stock Overview

Market Cap in USD	25,888m
Sub-Industry	Health Care Equipment
IPO / Inception	1992-06-01
Return 12m vs S&P 500	4.36%
Analyst Rating	3.80 of 5

STE Dividends

Dividend Yield	0.89%
Yield on Cost 5y	1.30%
Yield CAGR 5y	9.08%
Payout Consistency	96.9%
Payout Ratio	24.3%

STE Growth Ratios

CAGR	17.64%
CAGR/Max DD Calmar Ratio	0.89
CAGR/Mean DD Pain Ratio	2.59
Current Volume	876.1k
Average Volume	604.3k

Piotroski VR‑10 (Strict, 0-10) 9.0

Net Income (688.5m TTM) > 0 and > 6% of Revenue (6% = 342.2m TTM)

FCFTA 0.09 (>2.0%) and ΔFCFTA 2.59pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 21.35% (prev 22.55%; Δ -1.20pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.13 (>3.0%) and CFO 1.30b > Net Income 688.5m (YES >=105%, WARN >=100%)

Net Debt (-193.2m) to EBITDA (1.35b) ratio: -0.14 <= 3.0 (WARN <= 3.5)

Current Ratio 2.37 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (98.8m) change vs 12m ago -0.41% (target <= -2.0% for YES)

Gross Margin 44.29% (prev 43.00%; Δ 1.28pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 55.22% (prev 49.04%; Δ 6.19pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 10.60 (EBITDA TTM 1.35b / Interest Expense TTM 67.0m) >= 6 (WARN >= 3)

Altman Z'' 4.26

(A) 0.12 = (Total Current Assets 2.11b - Total Current Liabilities 888.9m) / Total Assets 10.41b

(B) 0.26 = Retained Earnings (Balance) 2.73b / Total Assets 10.41b

(D) 2.07 = Book Value of Equity 7.01b / Total Liabilities 3.39b

Total Rating: 4.26 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 69.35

1. Piotroski 9.0pt = 4.0

2. FCF Yield 3.74% = 1.87

3. FCF Margin 16.86% = 4.21

4. Debt/Equity 0.02 = 2.50

5. Debt/Ebitda -0.14 = 2.50

6. ROIC - WACC (= -3.59)% = -4.48

7. RoE 10.21% = 0.85

8. Rev. Trend 63.72% = 4.78

9. EPS Trend 62.30% = 3.11

What is the price of STE shares?

As of November 11, 2025, the stock is trading at USD 264.01 with a total of 876,067 shares traded.
Over the past week, the price has changed by +11.25%, over one month by +11.95%, over three months by +9.55% and over the past year by +20.21%.

Is STERIS a good stock to buy?

Partly, yes. Based on ValueRay´s Fundamental Analyses, STERIS (NYSE:STE) is currently (November 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 69.35 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of STE is around 263.98 USD . This means that STE is currently overvalued and has a potential downside of -0.01%.

Is STE a buy, sell or hold?

STERIS has received a consensus analysts rating of 3.80. Therefor, it is recommend to hold STE.

Strong Buy: 3
Buy: 2
Hold: 5
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the STE price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	278.4	5.4%
Analysts Target Price	278.4	5.4%
ValueRay Target Price	297.8	12.8%

STE Fundamental Data Overview November 10, 2025

Market Cap USD = 25.89b (25.89b USD * 1.0 USD.USD)
P/E Trailing = 37.7353
P/E Forward = 23.9234
P/S = 4.5399
P/B = 3.4317
P/EG = 1.8407
Beta = 1.026
Revenue TTM = 5.70b USD
EBIT TTM = 710.1m USD
EBITDA TTM = 1.35b USD
Long Term Debt = 1.92b USD (from longTermDebt, last fiscal year)
Short Term Debt = 159.2m USD (from shortTermDebt, last fiscal year)
Debt = 126.0m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -193.2m USD (from netDebt column, last quarter)
Enterprise Value = 25.70b USD (25.89b + Debt 126.0m - CCE 319.2m)
Interest Coverage Ratio = 10.60 (Ebit TTM 710.1m / Interest Expense TTM 67.0m)
FCF Yield = 3.74% (FCF TTM 961.2m / Enterprise Value 25.70b)
FCF Margin = 16.86% (FCF TTM 961.2m / Revenue TTM 5.70b)
Net Margin = 12.07% (Net Income TTM 688.5m / Revenue TTM 5.70b)
Gross Margin = 44.29% ((Revenue TTM 5.70b - Cost of Revenue TTM 3.18b) / Revenue TTM)
Gross Margin QoQ = 44.23% (prev 45.14%)
Tobins Q-Ratio = 2.47 (Enterprise Value 25.70b / Total Assets 10.41b)
Interest Expense / Debt = 11.83% (Interest Expense 14.9m / Debt 126.0m)
Taxrate = 23.94% (60.6m / 253.1m)
NOPAT = 540.1m (EBIT 710.1m * (1 - 23.94%))
Current Ratio = 2.37 (Total Current Assets 2.11b / Total Current Liabilities 888.9m)
Debt / Equity = 0.02 (Debt 126.0m / totalStockholderEquity, last quarter 7.01b)
Debt / EBITDA = -0.14 (Net Debt -193.2m / EBITDA 1.35b)
Debt / FCF = -0.20 (Net Debt -193.2m / FCF TTM 961.2m)
Total Stockholder Equity = 6.75b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.61% (Net Income 688.5m / Total Assets 10.41b)
RoE = 10.21% (Net Income TTM 688.5m / Total Stockholder Equity 6.75b)
RoCE = 8.19% (EBIT 710.1m / Capital Employed (Equity 6.75b + L.T.Debt 1.92b))
RoIC = 6.21% (NOPAT 540.1m / Invested Capital 8.70b)
WACC = 9.80% (E(25.89b)/V(26.01b) * Re(9.80%) + D(126.0m)/V(26.01b) * Rd(11.83%) * (1-Tc(0.24)))
Discount Rate = 9.80% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -0.28%
[DCF Debug] Terminal Value 75.95% ; FCFE base≈848.8m ; Y1≈1.05b ; Y5≈1.79b
Fair Price DCF = 227.5 (DCF Value 22.33b / Shares Outstanding 98.1m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 62.30 | EPS CAGR: 7.59% | SUE: 1.35 | # QB: 3
Revenue Correlation: 63.72 | Revenue CAGR: 6.88% | SUE: 0.26 | # QB: 0

Additional Sources for STE Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle